BSE Live
Apr 08, 16:01Prev. Close
72.92
Open Price
78.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 08, 15:43Prev. Close
73.23
Open Price
77.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
71.73 (5668)
| Key Financial Ratios of Brooks Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -13.84 | -9.20 | -8.53 | 1.03 | 6.57 | |
| Diluted EPS (Rs.) | -13.84 | -9.20 | -8.53 | 1.03 | 6.57 | |
| Cash EPS (Rs.) | -7.18 | -5.13 | -4.55 | 2.06 | 7.29 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 39.84 | 64.96 | 70.72 | 79.25 | 75.40 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 39.84 | 64.96 | 70.72 | 79.25 | 75.40 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 28.21 | 34.00 | 34.42 | 35.55 | 49.43 | |
| PBDIT/Share (Rs.) | -1.42 | -3.39 | -5.37 | 3.19 | 7.81 | |
| PBIT/Share (Rs.) | -4.11 | -7.40 | -9.35 | 2.16 | 7.10 | |
| PBT/Share (Rs.) | -5.47 | -9.23 | -10.83 | 1.53 | 6.68 | |
| Net Profit/Share (Rs.) | -9.87 | -9.15 | -8.53 | 1.03 | 6.57 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | -5.04 | -9.96 | -15.58 | 8.97 | 15.80 | |
| PBIT Margin (%) | -14.58 | -21.77 | -27.15 | 6.06 | 14.35 | |
| PBT Margin (%) | -19.39 | -27.16 | -31.47 | 4.31 | 13.52 | |
| Net Profit Margin (%) | -34.97 | -26.90 | -24.79 | 2.89 | 13.29 | |
| Return on Networth / Equity (%) | -24.76 | -14.08 | -12.06 | 1.29 | 8.71 | |
| Return on Capital Employed (%) | -9.06 | -9.94 | -11.44 | 1.19 | 8.53 | |
| Return on Assets (%) | -15.44 | -8.81 | -7.99 | 1.01 | 6.97 | |
| Total Debt/Equity (X) | 0.24 | 0.27 | 0.22 | 0.10 | 0.05 | |
| Asset Turnover Ratio (%) | 44.14 | 32.76 | 32.26 | 35.05 | 52.45 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 0.83 | 0.67 | 0.76 | 0.90 | 1.17 | |
| Quick Ratio (X) | 0.53 | 0.46 | 0.48 | 0.58 | 0.93 | |
| Inventory Turnover Ratio (X) | 5.06 | 5.47 | 4.88 | 7.47 | 11.96 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 60.28 | 111.06 | 152.70 | 230.15 | 142.52 | |
| EV/Net Operating Revenue (X) | 0.86 | 2.02 | 2.74 | 4.00 | 1.78 | |
| EV/EBITDA (X) | -17.14 | -20.24 | -17.58 | 44.57 | 11.27 | |
| MarketCap/Net Operating Revenue (X) | 0.54 | 1.57 | 2.32 | 3.81 | 1.74 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 0.38 | 0.82 | 1.13 | 1.71 | 1.14 | |
| Price/Net Operating Revenue | 0.54 | 1.57 | 2.32 | 3.81 | 1.74 | |
| Earnings Yield | -0.64 | -0.17 | -0.11 | 0.01 | 0.08 |
18.02.2026
Brooks Labs Consolidated December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
10.02.2026
Brooks Labs Standalone December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
04.12.2025
Brooks Labs Consolidated September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
27.11.2025
Brooks Labs Standalone September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
18.02.2026
Brooks Labs Consolidated December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
10.02.2026
Brooks Labs Standalone December 2025 Net Sales at Rs 16.57 crore, down 56.91% Y-o-Y
04.12.2025
Brooks Labs Consolidated September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
27.11.2025
Brooks Labs Standalone September 2025 Net Sales at Rs 23.45 crore, up 12.79% Y-o-Y
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
08.04.2026
07.04.2026
Kiran Mazumdar‑Shaw calls for new IPO rules to unlock India’s innovation potential in life sciences
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth